Clinical trials: Locally Advanced Gastric Adenocarcinoma
Metastatic Gastric Cancer, Adenocarcinoma of the Gastro-oesophageal Junction
Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer
Background: It is estimated that in the Netherlands each year approximately 900 patients with gastric cancer or adenocarcinoma of the gastro-oesophageal junction are candidates for chemotherapy.
- Trial name
- B-DOCT (NCT01359397)
- Testing
- Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab, Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab, Trastuzumab
- Where
- Netherlands
- Sponsor
- The Netherlands Cancer Institute
Cancer
Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer
RATIONALE: Massage therapy may help relieve symptoms associated with cancer. It is not yet known which type of massage therapy is more effective in treating the symptoms of patients with cancer.
- Trial name
- NCT00253708
- Testing
- management of therapy complications, massage therapy, pain therapy
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Beth Israel Deaconess Medical Center
Cancer of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery
The purpose of the study is to determine the most tolerable and safe dose of ZD6474 (Zactima, Vandetanib) when given with standard chemotherapy, radiation therapy and surgery in patients with cancer of the esophagus
- Conditions
- Cancer of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Cancer of the Stomach
- Trial name
- NCT01183559
- Testing
- Vandetanib, 5 Fluorouracil (FU), Carboplatin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Fox Chase Cancer Center
Gastric Adenocarcinoma, Esophagus Adenocarcinoma
Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer
Oxaliplatin ± nivolumab in combination with trifluridine/tipiracil or 5-fluorouracile (5-FU) in frail patients with advanced, recurrent or metastatic gastric, oesophageal or gastroesophageal junction cancer.
- Conditions
- Gastric Adenocarcinoma, Esophagus Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- Trial name
- LOGICAN (NCT05476796)
- Testing
- Trifluridine/Tipiracil, Oxaliplatin, FOLFOX regimen
- Where
- 28 sites in France
- Volunteers
- 118 people
- Sponsor
- UNICANCER
Esophageal Cancer, Gastric Cancer
Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00020787
- Testing
- G17DT Immunogen, cisplatin, fluorouracil
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Gastric / Gastroesophageal Junction Adenocarcinoma
A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or…
- Trial name
- NCT07449780
- Testing
- AK104(SC), AK104(IV), Capecitabine
- Volunteers
- 422 people
- Sponsor
- Akeso
Gastric Cancer, Hepatocellular Carcinoma
Personalized DC Vaccine for Postoperative Cancer
The study is aimed to the test efficacy and safety of neoantigen-primed dendritic cell (DC) cell vaccine therapy for postoperative locally advanced gastric cancer, hepatocellular carcinoma, lung cancer and colorectal cancer, and…
- Conditions
- Gastric Cancer, Hepatocellular Carcinoma, Non-Small-Cell Lung Cancer, Colon Rectal Cancer
- Trial name
- NCT04147078
- Testing
- DC vaccine subcutaneous administration
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sichuan University
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
The purpose of this study is to evaluate the efficacy and safety of Disitamab Vedotin Combined with Cadonilimab in subjects with HER2-expressing locally advanced or metastatic gastric cancer and gastroesophageal junction…
- Trial name
- NCT06221748
- Testing
- Disitamab Vedotin Injection, Cadonilimab Injection, Paclitaxel Injection
- Where
- 12 sites in China
- Volunteers
- 90 people
- Sponsor
- RemeGen Co., Ltd.
Neuroendocrine Cancer, Small Cell Lung Cancer
Hyperthermia/Thermal Therapy With Chemotherapy to Treat Inoperable or Metastatic Tumors
Thermal therapy (hyperthermia, or heat) increases chemotherapy cancer cell kill. By itself, thermal therapy can also kill cancer cells.
- Conditions
- Neuroendocrine Cancer, Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Gastric Cancer
- Trial name
- FR-WB-TT/che (NCT00178698)
- Testing
- thermochemotherapy, Cisplatin, Gemcitabine, Interferon-a
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- The University of Texas Health Science Center, Houston
Gastric Cancer, Neoadjuvant Chemotherapy
Dragon III-Phase 3: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer
DRAGON III research, Neoadjuvant Chemotherapy (FLOT versus SOX) for Gastric Cancer, is an investigator initiated; phase 3, open label, multi-center randomized controlled study.
- Trial name
- NCT04384601
- Testing
- Chemotherapy
- Where
- China
- Volunteers
- 246 people
- Sponsor
- Ruijin Hospital
Advanced Gastric Cancer
A Phase II Study of TACE Plus PD-1 Antibody in the Locally Advanced Stomach Adenocarcinoma
This study is a phase II, prospective, single-center, single-arm trial to evaluate the efficacy and safety of the combination of neoadjuvant transcatheter arterial chemoembolization (TACE) and PD-1 antibody Tislelizumab in the…
- Trial name
- NCT04799548
- Testing
- Transcatheter Arterial Chemoembolization, Tislelizumab
- Where
- China
- Volunteers
- 71 people
- Sponsor
- Shanghai Zhongshan Hospital
Esophageal Cancer, Gastric Cancer
Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have locally…
- Trial name
- NCT00005876
- Testing
- rubitecan
- Where
- United States
- Sponsor
- Astex Pharmaceuticals, Inc.
Locally Advanced or Metastatic Solid Tumors, NSCLC
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of enzelkitug when administered as a single agent and in combination with atezolizumab or pembrolizumab in adult…
- Conditions
- Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma
- Trial name
- NCT05581004
- Testing
- Enzelkitug, Atezolizumab, Pembrolizumab
- Where
- 36 sites in United States, Australia and 8 more
- Volunteers
- 165 people
- Sponsor
- Genentech, Inc.
Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma
FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer
This randomized phase II trial studies how well fludeoxyglucose F-18 (FDG)/positron emission tomography (PET) directed treatment improves response in patients with stomach or gastroesophageal junction cancer that has not spread…
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma, Gastric Cancer
- Trial name
- NCT02485834
- Testing
- FDG-PET, surgery, 5-FU
- Where
- 71 sites in United States
- Volunteers
- 5 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma Cancer
Early Access Program for Zolbetuximab
This program is to provide zolbetuximab to people with stomach cancer or gastroesophageal junction (the junction between stomach and esophagus) cancer who have not yet been treated with chemotherapy, immunotherapy, or…
- Conditions
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma Cancer, Metastatic Gastric Adenocarcinoma Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
- Trial name
- NCT06048081
- Testing
- zolbetuximab
- Where
- 140 sites in United States, Brazil and 4 more
- Sponsor
- Astellas Pharma Global Development, Inc.
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer
The main purpose of this study is to evaluate the efficacy of an alternative dose of ramucirumab in combination with paclitaxel in participants with second-line metastatic or locally advanced, unresectable gastric or…
- Trial name
- NCT02514551
- Testing
- Ramucirumab, Paclitaxel
- Where
- 52 sites in United States, Belgium and 9 more
- Volunteers
- 245 people
- Sponsor
- Eli Lilly and Company
Stomach Neoplasms
Docetaxel in Locally Advanced Gastric Adenocarcinoma
Study objectives: To determine Ro resection rate of Docetaxel, cisplatin and fluorouracil combination for the treatment of neoadjuvant gastric carcinoma.
- Trial name
- NEOTAX (NCT00343239)
- Testing
- Docetaxel, Cisplatin, Fluorouracil
- Where
- Turkey (Türkiye)
- Volunteers
- 59 people
- Sponsor
- Sanofi
Gastric Cancer, Gastric Adenocarcinoma
A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer
A Phase 2, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal…
- Conditions
- Gastric Cancer, Gastric Adenocarcinoma, GastroEsophageal Cancer
- Trial name
- DisTinGuish (NCT04363801)
- Testing
- DKN-01 300mg, DKN-01 600mg, DKN-01 400mg
- Where
- 48 sites in United States, Germany and 1 more
- Volunteers
- 247 people
- Sponsor
- Leap Therapeutics, Inc.
Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach
Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer
This phase II trial is studying how well saracatinib works in treating patients with locally advanced or metastatic stomach or gastroesophageal junction cancer.
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage III Gastric Cancer
- Trial name
- NCT00607594
- Testing
- saracatinib
- Where
- 5 sites in United States, Canada
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
This randomized phase II trial studies how well docetaxel, oxaliplatin, capecitabine, fluorouracil, and radiation therapy works compared with fluorouracil when given together with oxaliplatin and radiation therapy in treating…
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT00938470
- Testing
- capecitabine, docetaxel, fluorouracil
- Where
- 187 sites in United States
- Volunteers
- 73 people
- Sponsor
- Alliance for Clinical Trials in Oncology